PCA
HZNP

Providence Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Providence Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13
Closed -$1K – 478
2022
Q1 		$1K Buy
+13
New +$1.27K ﹤0.01% 451

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Providence Capital Advisors's HZNP Position: Q2 2022 in Review

Providence Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 13 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in HZNP in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Providence Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 13 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Providence Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q1 2022.
  • 616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.